Nature medicine
BCMA-directed mRNA CAR T cell therapy for myasthenia gravis: a randomized, double-blind, placebo-controlled phase 2b trial.
Tuan Vu, Hacer Durmus, Michael Rivner, Sheetal Shroff, Thomas Ragole, Bennett Myers, Mamatha Pasnoor, George Small, Chafic Karam, Mithila Vullaganti, Amanda Peltier, Gregory Sahagian, Marc H Feinberg, Adam Slanksy, Carolina Barnett-Tapia
Published: 202610.1038/s41591-025-04171-y
Abstract
Myasthenia gravis (MG) is driven by the secretion of autoantibodies from pathogenic B cell maturation antigen (BCMA)-expressing plasma cells. In this phase 2b randomized, controlled, double-blind trial, we evaluated Descartes-08, an autologous BCMA-d…
Preview only. Read the full abstract at the source